Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024GlobeNewsWire • 11/05/24
Genentech to Present New and Encouraging Long-term Follow-up Data Across Broad Hematology Portfolio at ASH 2024Business Wire • 11/05/24
PredicineCARE™ Liquid Biopsy Assay Featured in NEJM as Pivotal Tool in Roche's Phase III Itovebi Breast Cancer TrialGlobeNewsWire • 11/04/24
Antibody-Drug Conjugates (ADC) Technology Research and Global Markets Report 2024-2025 & 2029 with Profiles of Leading Players - F. Hoffmann-La Roche.GlobeNewsWire • 11/04/24
Roche Holding AG (RHHBY) Virtual Neurology Investor Event Conference TranscriptSeeking Alpha • 11/02/24
Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer's diseaseGlobeNewsWire • 10/31/24
New England Journal of Medicine publishes landmark phase III results for Roche's Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancerGlobeNewsWire • 10/31/24
New England Journal of Medicine Publishes Landmark Phase III Results for Genentech's Itovebi, Showing More Than Doubling of Progression-Free Survival in Certain Type of HR-Positive Advanced Breast CancerBusiness Wire • 10/30/24
Dyno Therapeutics Forms New Strategic Partnership With Roche To Advance AAV Gene Therapy Vectors For Neurological DiseasesBusiness Wire • 10/24/24
Vabysmo, Hemlibra Drive Roches Sales in Q3 & First 9 Months of 2024Zacks Investment Research • 10/23/24
Roche Retains Outlook After Two Out Of Three Big Hitters Top Sales ExpectationsInvestors Business Daily • 10/23/24
[Ad hoc announcement pursuant to Art. 53 LR] Roche's strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine monthsGlobeNewsWire • 10/23/24
Roche's Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind studyGlobeNewsWire • 10/18/24
Genentech's Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind StudyBusiness Wire • 10/18/24
Roche receives FDA approval for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOYPRNewsWire • 10/18/24
Majority of children with spinal muscular atrophy (SMA) treated with Roche's Evrysdi are able to sit, stand and walk independently, two-year data demonstrateGlobeNewsWire • 10/14/24